首頁 > 市場調查報告書 > 製藥

處方藥

市場調查報告書

商品編碼

1535642

代謝紊亂治療市場 - 按疾病、治療、給藥途徑、最終用戶、全球預測

Metabolic Disorder Therapeutics Market - By Disease, Therapy, Route of Administration, End-user, Global Forecast 2024-2032

出版日期: 2024年06月10日 | 出版商:

Global Market Insights Inc. | 英文 195 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

在製藥和生技公司為促進創新而對研發進行大量投資的帶動下，代謝紊亂治療市場規模在 2024 年至 2032 年間將實現 7.5% 的複合年成長率。舉個例子，2023年11月，Biolexis Therapeutics, Inc.獲得了1000萬美元的資金，用於推進其代謝藥物的開發。產業參與者和學術界之間不斷加強的合作也為代謝紊亂治療的新發現和進步鋪平了道路。臨床試驗的增加正在擴大潛在治療的管道，為患者提供新的選擇，進一步塑造市場成長。

代謝紊亂治療行業按疾病、治療類型、給藥途徑、最終用戶和地區進行分類。

就疾病而言，由於藥物治療、手術技術和改善患者預後的綜合護理模式的進步，肥胖細分市場的市場規模可能在2024年至2032年錄得強勁的複合年成長率。遺傳和微生物組的新興研究也正在影響未來的突破，使肥胖管理更加有效和個人化，從而促進該細分市場的成長。

對於最終用戶來說，專科診所領域的代謝紊亂治療產業價值將在 2032 年之前擴大，因為他們越來越傾向於提供專業、全面和以患者為中心的護理。專科診所正在積極實施代謝性疾病的創新療法和治療方法，例如使用新型藥物、微創手術和先進的手術技術。這些診所還提供慢性護理管理計劃，以監測進度、根據需要調整治療計劃，並及時解決任何新出現的健康問題。

到2032年，亞太地區代謝紊亂治療市場規模可能會出現顯著的複合年成長率。等代謝紊亂的負擔日益增加。不斷湧現的政府措施和公共衛生運動在教育民眾了解代謝紊亂方面也發揮著至關重要的作用，促進了區域產業的成長。

產業生態系統分析
產業影響力
- 成長動力
  - 代謝紊亂的盛行率不斷增加
  - 開發新療法的研發活動不斷增加
  - 提高認知和篩檢計劃
- 產業陷阱與挑戰
  - 治療費用高
  - 嚴格的監管要求
成長潛力分析
監管環境
技術景觀
管道分析
波特的分析
PESTEL分析

第 4 章：競爭格局

介紹
公司市佔率分析
公司矩陣分析
主要市場參與者的競爭分析
競爭定位矩陣
戰略儀表板

第 5 章：市場估計與預測：按疾病分類，2021 - 2032 年

主要趨勢
糖尿病
高膽固醇血症
溶小體貯積症
- 戈謝氏症
- 異染性腦白質營養不良
- 投手-謝伊
- 桑菲利波A
- 其他溶小體貯積症
肥胖
遺傳性代謝紊亂

第 6 章：市場估計與預測：按治療類型，2021 - 2032 年

主要趨勢
藥物治療
酵素替代療法
底物減少療法
基因治療
基於小分子的治療
細胞移植

第 7 章：市場估計與預測：按管理途徑，2021 - 2032 年

主要趨勢
口服
注射用
其他給藥途徑

第 8 章：市場估計與預測：按最終用戶分類，2021 - 2032 年

主要趨勢
醫院
專科診所
其他最終用戶

第 9 章：市場估計與預測：按地區分類，2021 - 2032 年

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 10 章：公司簡介

AbbVie, Inc.
Actelion Pharmaceuticals Ltd.
Amgen Inc.
AstraZeneca plc
Biocon Ltd.
BioMarin Pharmaceutical, Inc.
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Cipla, Inc.
CymaBay Therapeutics, Inc.
Eli Lilly and Company
Merck KGaA
Novo Nordisk A/S
Sanofi SA
Shire PLC

簡介目錄

Product Code: 9801

Metabolic Disorder Therapeutics Market size will record 7.5% CAGR between 2024 and 2032, led by significant investments in R&D by pharmaceutical and biotechnology companies to foster innovations. To cite an instance, in November 2023, Biolexis Therapeutics, Inc. secured $10 million in funding to advance its metabolic drug development. Rising collaborations between the industry players and academia are also making way for new discoveries and advancements in metabolic disorder therapeutics. The increase in clinical trials is expanding the pipeline of potential treatments for providing new options for patients, further shaping the market growth.

The metabolic disorder therapeutics industry is classified into disease, therapy type, route of administration, end-user, and region.

In terms of disease, the market size from the obesity segment may record a robust CAGR from 2024 to 2032 owing to the advances in pharmacotherapy, surgical techniques, and integrated care models for improving outcomes for patients. The emerging research in genetic and microbiome is also influencing future breakthroughs, making the management of obesity more effective and personalized, subsequently adding to the segment growth.

By end-user, the metabolic disorder therapeutics industry value from the specialty clinics segment will expand through 2032, due to their rising preference for offering specialized, comprehensive, and patient-centered care. Specialty clinics are actively implementing innovative therapies and treatments for metabolic disorders, such as the use of novel pharmacological agents, minimally invasive procedures, and advanced surgical techniques. These clinics also offer chronic care management programs to monitor progress, adjust treatment plans as needed, and address any emerging health issues promptly.

Asia Pacific metabolic disorder therapeutics market size may witness significant CAGR through 2032. This can mainly be ascribed to the increasing burden of metabolic disorders like diabetes, obesity, hyperlipidemia, and metabolic syndrome driven by changing lifestyles, dietary habits and the aging population. The surging government initiatives and public health campaigns are also playing a crucial role in educating the population about metabolic disorders, adding to the regional industry growth.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of metabolic disorders
  - 3.2.1.2 Rising R&D activities for developing novel therapeutics
  - 3.2.1.3 Growing awareness and screening programs
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 High cost associated with treatment
  - 3.2.2.2 Stringent regulatory requirements
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technological landscap
3.6 Pipeline analysis
3.7 Porter's analysis
3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Disease, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Diabetes
5.3 Hypercholesterolemia
5.4 Lysosomal storage diseases
- 5.4.1 Gaucher's disease
- 5.4.2 Metachromatic leukodystrophy
- 5.4.3 Hurler - Scheie
- 5.4.4 Sanfilipo A
- 5.4.5 Other lysosomal storage diseases
5.5 Obesity
5.6 Inherited metabolic disorders

Chapter 6 Market Estimates and Forecast, By Therapy Type, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Drug therapy
6.3 Enzyme replacement therapy
6.4 Substrate reduction therapy
6.5 Gene therapy
6.6 Small molecule-based therapy
6.7 Cellular transplantation

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Oral
7.3 Parenteral
7.4 Other routes of administration

Chapter 8 Market Estimates and Forecast, By End-User, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Hospitals
8.3 Specialty clinics
8.4 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa